369 related articles for article (PubMed ID: 18028530)
1. Moderators of naltrexone's effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment.
Tidey JW; Monti PM; Rohsenow DJ; Gwaltney CJ; Miranda R; McGeary JE; MacKillop J; Swift RM; Abrams DB; Shiffman S; Paty JA
Alcohol Clin Exp Res; 2008 Jan; 32(1):58-66. PubMed ID: 18028530
[TBL] [Abstract][Full Text] [Related]
2. Genetic moderators of naltrexone's effects on alcohol cue reactivity.
McGeary JE; Monti PM; Rohsenow DJ; Tidey J; Swift R; Miranda R
Alcohol Clin Exp Res; 2006 Aug; 30(8):1288-96. PubMed ID: 16899031
[TBL] [Abstract][Full Text] [Related]
3. Polymorphisms of the mu-opioid receptor and dopamine D4 receptor genes and subjective responses to alcohol in the natural environment.
Ray LA; Miranda R; Tidey JW; McGeary JE; MacKillop J; Gwaltney CJ; Rohsenow DJ; Swift RM; Monti PM
J Abnorm Psychol; 2010 Feb; 119(1):115-25. PubMed ID: 20141248
[TBL] [Abstract][Full Text] [Related]
4. Naltrexone modification of drinking effects in a subacute treatment and bar-lab paradigm: influence of OPRM1 and dopamine transporter (SLC6A3) genes.
Anton RF; Voronin KK; Randall PK; Myrick H; Tiffany A
Alcohol Clin Exp Res; 2012 Nov; 36(11):2000-7. PubMed ID: 22551036
[TBL] [Abstract][Full Text] [Related]
5. Variation in OPRM1 moderates the effect of desire to drink on subsequent drinking and its attenuation by naltrexone treatment.
Kranzler HR; Armeli S; Covault J; Tennen H
Addict Biol; 2013 Jan; 18(1):193-201. PubMed ID: 22784013
[TBL] [Abstract][Full Text] [Related]
6. Real-time assessment of alcohol craving and naltrexone treatment responsiveness in a randomized clinical trial.
Miranda R; Treloar Padovano H; Gray JC; Wemm SE; Blanchard A
Addict Behav; 2018 Aug; 83():72-78. PubMed ID: 29395188
[TBL] [Abstract][Full Text] [Related]
7. Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder.
Hartwell EE; Feinn R; Morris PE; Gelernter J; Krystal J; Arias AJ; Hoffman M; Petrakis I; Gueorguieva R; Schacht JP; Oslin D; Anton RF; Kranzler HR
Addiction; 2020 Aug; 115(8):1426-1437. PubMed ID: 31961981
[TBL] [Abstract][Full Text] [Related]
8. Does family history of alcoholism moderate naltrexone's effects on alcohol use?
Capone C; Kahler CW; Swift RM; O'Malley SS
J Stud Alcohol Drugs; 2011 Jan; 72(1):135-40. PubMed ID: 21138720
[TBL] [Abstract][Full Text] [Related]
9. Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study.
Ray LA; Hutchison KE
Arch Gen Psychiatry; 2007 Sep; 64(9):1069-77. PubMed ID: 17768272
[TBL] [Abstract][Full Text] [Related]
10. Naltrexone improves quit rates, attenuates smoking urge, and reduces alcohol use in heavy drinking smokers attempting to quit smoking.
Fridberg DJ; Cao D; Grant JE; King AC
Alcohol Clin Exp Res; 2014 Oct; 38(10):2622-9. PubMed ID: 25335648
[TBL] [Abstract][Full Text] [Related]
11. The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking.
Pettinati HM; O'Brien CP; Rabinowitz AR; Wortman SP; Oslin DW; Kampman KM; Dackis CA
J Clin Psychopharmacol; 2006 Dec; 26(6):610-25. PubMed ID: 17110818
[TBL] [Abstract][Full Text] [Related]
12. Influence of the A118G Polymorphism of the OPRM1 Gene and Exon 3 VNTR Polymorphism of the DRD4 Gene on Cigarette Craving After Alcohol Administration.
Lechner WV; Knopik VS; McGeary JE; Spillane NS; Tidey JW; McKee SA; Metrik J; Leventhal AM; Rohsenow DJ; Kahler CW
Nicotine Tob Res; 2016 May; 18(5):632-6. PubMed ID: 26092968
[TBL] [Abstract][Full Text] [Related]
13. An analysis of the effect of mu-opioid receptor gene (OPRM1) promoter region DNA methylation on the response of naltrexone treatment of alcohol dependence.
Lin Y; Kranzler HR; Farrer LA; Xu H; Henderson DC; Zhang H
Pharmacogenomics J; 2020 Oct; 20(5):672-680. PubMed ID: 32029903
[TBL] [Abstract][Full Text] [Related]
14. Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues.
Schacht JP; Anton RF; Voronin KE; Randall PK; Li X; Henderson S; Myrick H
Neuropsychopharmacology; 2013 Feb; 38(3):414-22. PubMed ID: 23032071
[TBL] [Abstract][Full Text] [Related]
15. Extended-release vs. oral naltrexone for alcohol dependence treatment in primary care (XON).
Malone M; McDonald R; Vittitow A; Chen J; Obi R; Schatz D; Tofighi B; Garment A; Kermack A; Goldfeld K; Gold H; Laska E; Rotrosen J; Lee JD
Contemp Clin Trials; 2019 Jun; 81():102-109. PubMed ID: 30986535
[TBL] [Abstract][Full Text] [Related]
16. Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study.
Gelernter J; Gueorguieva R; Kranzler HR; Zhang H; Cramer J; Rosenheck R; Krystal JH;
Alcohol Clin Exp Res; 2007 Apr; 31(4):555-63. PubMed ID: 17374034
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of extended-release naltrexone in patients with relatively higher severity of alcohol dependence.
Pettinati HM; Silverman BL; Battisti JJ; Forman R; Schweizer E; Gastfriend DR
Alcohol Clin Exp Res; 2011 Oct; 35(10):1804-11. PubMed ID: 21575016
[TBL] [Abstract][Full Text] [Related]
18. Family history and antisocial traits moderate naltrexone's effects on heavy drinking in alcoholics.
Rohsenow DJ; Miranda R; McGeary JE; Monti PM
Exp Clin Psychopharmacol; 2007 Jun; 15(3):272-81. PubMed ID: 17563214
[TBL] [Abstract][Full Text] [Related]
19. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study.
Anton RF; Oroszi G; O'Malley S; Couper D; Swift R; Pettinati H; Goldman D
Arch Gen Psychiatry; 2008 Feb; 65(2):135-44. PubMed ID: 18250251
[TBL] [Abstract][Full Text] [Related]
20. Influence of combined treatment with naltrexone and memantine on alcohol drinking behaviors: a phase II randomized crossover trial.
Krishnan-Sarin S; O'Malley SS; Franco N; Cavallo DA; Tetrault JM; Shi J; Gueorguieva R; Pittman B; Krystal JH
Neuropsychopharmacology; 2020 Jan; 45(2):319-326. PubMed ID: 31590179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
